Leena Shahla, MD, is the medical director at the Duke Pituitary Center and an associate professor of medicine and neurosurgery at Duke University.

Real-World Data Reinforces Paltusotine’s IGF-1 Reductions in Acromegaly, With Leena Shahla, MD

Paltusotine reduces insulin-like growth factor 1 (IGF-1) levels in adult patients with 

 while lessening treatment burden and without new safety signals, based on a recent study.

American Association of Clinical Endocrinology (AACE) Annual Meeting 2026

 in Las Vegas, Nevada, by Leena Shahla, MD, medical director at the Duke Pituitary Center and associate professor of medicine and neurosurgery at Duke University, these data highlight the safety and efficacy of paltusotine, as well as its capacity for reducing injection burden in adult patients.

“These injections are not easy – they’re painful, they may cause bruises, tenderness, patients worry about where and how to take them,” Shahla told 

 in an exclusive interview. “They may need an office visit every month to take the injection, or they may need home visits by a nurse to help with the injection, which will affect their schedule. Having another option like paltusotine, an oral medication, is excellent for patients.”

, under the name PALSONIFY. The decision was based on a pair of pivotal phase 3 trials, PATHFNDR-1 and PATHFNDR-2, which displayed paltusotine’s safety and efficacy in medically untreated adults with acromegaly. Paltusotine exhibited rapid onset, sustained efficacy, and reliable biochemical control throughout both trials.

The present study included adult patients with a confirmed diagnosis of acromegaly who had been prescribed paltusotine at 1 of 3 US-based pituitary centers and who had ≥1 IGF-1 level available after drug initiation. Medical records were scanned for demographic and clinical characteristics, treatment history, IGF-1 levels, acromegaly symptoms, and paltusotine dosing.

A total of 6 patients were enrolled in the study. Patient ages ranged from 25 to 58 years, and all patients had undergone a prior pituitary adenoma resection. 3 of these patients had no history of acromegaly medications, while the others had received and eventually discontinued lanreotide, ocreotide, carbergoline, or any combination of these drugs. Each patient received a dose of paltusotine between 20 and 40 mg per day.

At baseline, IGF-1 levels ranged from 304 to 674 ng/mL. After 3-4 weeks, IGF-1 levels dropped to around 164-281 ng/mL in all but 1 patient. The upper limit of normalized IGF-1 ranged from 328 to 347 ng/mL across all 3 study centers.

Additionally, Shahla and colleagues analyzed individual patient outcomes before and after treatment. After 3-4 weeks of treatment, patient 1 saw more regular menses, resolved joint pain, and increased energy, among other outcomes. Patient 2 saw improved sleep and sleep apnea, improved blood pressure, smoother facial features, and increased energy. Patient 3 saw a reduction in speech slurring and resolution of headaches, while patient 4 saw improved sleep and decreased joint pain and sweating. Patient 5 saw their hand joint pains resolved and their headaches improved, while Patient 6 saw improved blood glucose levels after treatment.

Shalha and colleagues determined that this study proved paltusotine’s efficacy and reinforced its safety profile. However, the team also encourages additional real-world studies, including larger sample sizes.

“Rather than worrying or going through the struggles with the injections and the pain and the hassle, taking oral medication is easier,” Shahla said. “It’s more convenient, and it will maintain their biochemical and symptom control. If a patient would rather avoid an injection, they now have the option to.”

Editors’ Note: Shahla reports disclosures with Camurus, Chiesi Farmaceutici, Crinetics Pharmaceuticals, and Recordati Rare Diseases.

Shahla L, Galbiati F, Blevins L, Yuen K. Once-Daily Oral Paltusotine in the Treatment of Adults With Acromegaly: Initial Real-World Experience. Presented at the American Association of Clinical Endocrinology Annual Meeting 2026, Las Vegas, NV. April 22-24, 2026.

Crinetics Pharmaceuticals. Crinetics Announces FDA Approval of PALSONIFY (paltusotine) for the Treatment of Acromegaly in Adults. September 25, 2025. Accessed April 30, 2026. 

https://crinetics.com/press-releases/crinetics-announces-fda-approval-of-palsonify-paltusotine-for-the-treatment-of-acromegaly-in-adults/

Videos

Shahla discusses a recent real-world study analyzing the clinical outcomes of patients prescribed paltusotine after its September 2025 approval.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Hormonal Disorders

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Adriana Le Thanh-Thao, MBBS, FRACP, from the Royal Hobart Hospital Jack Jumper Allergy Program.

demonstrated similar protection to standard 50 mcg dosing, with 85% of participants tolerating a sting challenge after 12 months.

These findings come from a phase 1/2 single-blind randomized controlled trial of 49 adults aged 18 – 65 years with prior systemic allergic reactions to JJA stings, with 44 initiating treatment (either 25 mcg venom + delta-inulin (n = 10), 25 mcg venom with no delta-inulin (n = 11), 50 mcg venom + delta-inulin (n = 12), or 50 mcg venom with no delta-inulin (n = 11)) and 40 undergoing a sting challenge. Investigators observed no difference between dosing groups (odds ratio [OR], 0.89; 95% CI, 0.38–2.09; 

 =.98) or with the addition of delta-inulin (Advax) (OR, 0.99; 95% CI, 0.42–2.33). Greater dosing reduced systemic reactions (OR, 0.53; 95% CI, 0.28–0.98).

 spoke with investigator Adriana Le Thanh-Thao, MBBS, FRACP, from the Royal Hobart Hospital Jack Jumper Allergy Program to contextualize these findings for clinical practice. In this Q&A, Le Thanh-Thao discussed dose selection, safety trade-offs, the role of delta-inulin, and how clinicians should interpret emerging biomarker data in venom immunotherapy.

 What do the findings suggest about the comparative efficacy of 25 mcg versus 50 mcg maintenance dosing for jack jumper ant venom immunotherapy?

 85% of participants who completed the trial protocol passed [the] deliberate sting challenge after 12 months of maintenance [with] JJA VIT. The sting challenge outcomes were similar between the 25mcg and 50mcg VIT groups, suggesting low-dose JJA VIT may be non-inferior to the current standard dose.

 Given similar efficacy, what are the potential advantages and trade-offs of using a lower 25 mcg maintenance dose in clinical practice?

 JJA venom for VIT is costly and resource-intensive to produce. A lower maintenance dose would be associated with significant healthcare savings for the institutions providing JJA VIT and potentially increase the capacity to treat more patients.

Shortages of JJA venom are a risk, as there is only one manufacturer of the product, and a lower maintenance dose would mitigate the impact of a shortage should it occur.

It is unknown if the 25 mcg dose is protective against multiple stings or will be less likely than higher VIT doses to induce mechanisms of long-term immune tolerance, which are desired to provide ongoing protection from stings after completing a 3–5-year course of VIT.

While we expected a lower VIT dose to be associated with [fewer] allergic side effects (as has previously been found when comparing 50 mcg vs. 100 mcg JJA VIT), in our current study, systemic allergic reactions were more common with the lower VIT dose. Further studies would be required to determine if this is a true effect, in which case it may reflect the observation that some patients require a higher VIT dose compared to others to induce tolerance.

 How did the addition of delta-inulin influence clinical outcomes, and should it be considered in routine venom immunotherapy protocols?

 Advax enhanced sIgG4 responses when combined with the standard JJA VIT dose, but this did not correlate with an improvement in clinical outcome in terms of either efficacy or treatment-related side effects. As a result, it should not yet be considered in routine VIT protocols. Advax may still have immunomodulatory benefits with longer-term VIT treatment, including after cessation of treatment, but this would require further studies.

 How should clinicians weigh the finding that greater maintenance dosing was associated with fewer treatment-related systemic reactions?

 The number of participants in this study was relatively small, so it is possible this is a chance result, and a larger study would be required to confirm this finding. However, it is well recognized that some bee and wasp venom-allergic patients do not have clinical protection with standard 100 mcg maintenance dosing, which is evidenced by systemic reactions to VIT or stings while in the maintenance phase of therapy. Increasing to a higher VIT maintenance dose (e.g., 200 mcg) in these patients has been shown to confer protection. It may be a similar scenario with the low-dose JJA VIT patients having systemic reactions to VIT, requiring a higher dose to induce tolerance.

 What do the safety data indicate about the risk of systemic reactions during the build-up versus maintenance phases of therapy?

 Systemic reactions are most common during the build-up phase and uncommon during the maintenance phase of therapy. While systemic reactions to JJA VIT are common, occurring in around one-third of patients when using a semi-rush build-up protocol, the majority of these reactions are mild and non-recurrent.

 How might basophil activation test trends inform clinical decision-making or risk stratification in venom immunotherapy?

 This study found a decrease in basophil activation from baseline was associated with having a negative sting challenge after 12 months of VIT. A decline in BAT sensitivity, therefore, has the potential [to be] a biomarker for predicting the development of clinical tolerance to stings. However, these findings would need to be replicated in larger studies to confirm BAT’s robustness as a biomarker of successful VIT.

 In the absence of clear biomarker predictors, how should clinicians currently assess treatment success and protection against future stings?

 At present, there is still no established biomarker for gauging VIT success, which is instead assessed clinically by reactivity to stings (either accidental field stings or with deliberate sting challenge) during and after a course of VIT. However, while stings are the ‘gold standard’ test, they have some limitations in regard to their negative predictive value. Tolerance to a single sting during or following a course of VIT is still not a guarantee of tolerance to subsequent stings, as the natural history of reactivity to stings is variable in allergic patients, who may tolerate their next sting [and] then react to a subsequent sting.

 Based on these findings, is there sufficient evidence to support adopting lower-dose venom immunotherapy?

 This was a pilot phase 1/2 study, and the number of participants was relatively small. Larger studies would be required to confirm the non-inferiority of lower VIT dosing.

Le TA, Wanandy T, Perkins GB, et al. A Pilot Randomised Controlled Dose-Ranging Trial of Ant Venom Immunotherapy With and Without Delta-Inulin Adjuvant. 

Articles

Q&A with Le Thanh-Thao on trial data showing 25 mcg of JJA VIT matched 50 mcg efficacy, with safety and biomarker insights.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

25 mcg JJA Venom Immunotherapy Matches 50 mcg Efficacy, With Adriana Le Thanh-Thao, MBBS

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Credit: University of California, San Diego

In the phase 2 RAPIDe-1 trial, oral deucrictibant significantly reduced the severity of 

attacks in 4 hours compared with the placebo.

“…these results support continued investigation of antagonism of the bradykinin B2 receptor with an orally available agent as a potentially effective approach, with a safety profile similar to placebo, for on-demand treatment,” wrote study investigators Marc A. Riedl, from the University of California San Diego; Emel Aygören-Pürsün, MD, from Goethe University Frankfurt; and colleagues.

Before the publication of this phase 2 data, Pharvaris announced that oral deucrictibant 20 mg met its primary endpoint in the placebo-controlled phase 3 trial, showing symptom relief in under 90 minutes.

The mean time to symptom relief with oral deucrictibant was within 1.28 hours, compared to > 12 hours with a placebo.

In the recently published phase 2 randomized, double-blind, placebo-controlled, crossover study, adults with HAE type 1 or 2 experienced clinically meaningful improvements in symptom burden and time to relief when treated with deucrictibant at doses of 20 mg or 30 mg.

 Among 62 patients included in the modified intention-to-treat analysis, deucrictibant demonstrated significant reductions in the composite visual analog scale (VAS-3) score at 4 hours compared with the placebo. Least squares mean differences were −15.02 (95% CI, −20.22 to −9.81; 

<.0001) for 20 mg and −16.28 (95% CI, −21.27 to −11.29; 

<.0001) for 30 mg. A 10 mg dose showed similar directional effects but was evaluated descriptively.

Clinical benefits extended to key secondary endpoints. Median time to onset of symptom relief, defined as a ≥ 30% reduction in VAS-3, was 2.7 hours for 20 mg and 2.5 hours for 30 mg, compared with 8.0 hours for placebo. Time to a ≥ 50% reduction in symptoms and to near-complete or complete resolution was also significantly shorter with deucrictibant. Within 24 hours, 71% of attacks treated with 20 mg and 74% with 30 mg achieved near-complete or complete resolution without rescue medication, compared with 16% of placebo-treated attacks.

Use of rescue therapy was lower with deucrictibant. Within 24 hours, 11% and 13% of attacks treated with 20 mg and 30 mg, respectively, required rescue medication versus 73% with placebo (odds ratios 0.05–0.06; 

<.0001). These findings suggest both rapid onset and durability of response.

The study reported no grade 3 or higher treatment-emergent adverse events. Most adverse events were mild to moderate and considered unrelated to the study drug. In part 2 of the trial, no single adverse event occurred in ≥ 2 patients within any treatment group. Oral administration avoids injection-site reactions commonly associated with subcutaneous bradykinin B2 receptor antagonists.

Pharmacokinetic data showed plasma concentrations exceeding the estimated threshold for 85% maximal response within 15 to 30 minutes of dosing, aligning with observed early clinical effects. Symptom improvement was detectable within the first hour across multiple outcome measures.

Current on-demand HAE therapies, including C1 esterase inhibitors, icatibant, and ecallantide, require intravenous or subcutaneous administration, which can delay treatment initiation. Although the recently approved plasma kallikrein inhibitor sebetralstat offers an oral option, deucrictibant represents the first oral bradykinin B2 receptor antagonist evaluated in a randomized controlled trial for acute HAE treatment, according to the investigators.

The team noted several limitations, including the exclusion of laryngeal attacks and those with vomiting, limiting generalizability to greater risk presentations. The study population was predominantly White, and the attack location was not randomized, which may influence response patterns.

Ongoing phase 3 studies are expected to further define the role of deucrictibant in both on-demand and prophylactic HAE treatment strategies. Investigators noted that the phase 3 trial will include a broader geographical and racial representation.

“Together with the results of the CHAPTER-1 trial (NCT05047185) for prophylaxis of angioedema attacks conducted in parallel, outcomes of RAPIDe-1 provide the first clinical evidence, to our knowledge, that antagonism of the bradykinin B2 receptor with deucrictibant could be effective and well tolerated and that deucrictibant might be the first oral therapy for both prevention and treatment of bradykinin-mediated angioedema attacks,” investigators concluded.

Maurer M, Stobiecki M, Valerieva A, et al. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial. 

Derman C. Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial. HCPLive. Published December 8, 2025. Accessed on April 29, 2026. 

https://www.hcplive.com/view/pharvaris-deucrictibant-provides-rapid-relief-hae-phase-3-rapide-3-trial

Oral deucrictibant, a bradykinin B2 receptor antagonist, produced rapid, clinically meaningful improvement in acute hereditary angioedema (type 1/2), significantly lowering composite VAS symptom burden by 4 hours versus placebo. Median onset of relief occurred ~2.5–2.7 hours with 20–30 mg versus 8 hours with placebo, with markedly higher near-complete/complete resolution by 24 hours and substantially reduced rescue-medication use. Pharmacokinetics supported early efficacy, and tolerability was placebo-like without grade ≥3 events. Phase 3 data suggest symptom relief within ~90 minutes.

Phase 2 RAPIDe-1 trial shows an oral bradykinin B2 antagonist improves symptom relief and reduces rescue therapy use in hereditary angioedema attacks.

Oral Deucrictibant Reduces HAE Attack Severity in 4 Hours During Phase 2 RAPIDe-1

Mark G. Lebwohl, MD, the dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai,

Patient Preferences and Shared Decision-Making in Psoriasis Care

In this episode, ‘Patient Preferences and Shared Decision-Making in Psoriasis Care,’ the expert dermatologists explore the nuanced process of transition from topical to systemic therapy. Dr. Mark Lebwohl explains that while a 10% body surface area (BSA) often serves as a traditional threshold, systemic treatment is frequently necessary for patients with lower BSA if the psoriasis affects high-impact areas like the palms, soles, genitals, or hairline. He emphasizes that the National Psoriasis Foundation provides crucial support for clinicians to advocate for systemic options when a patient’s quality of life is significantly impaired, regardless of objective coverage scores.

Dr. Tina Bhutani-Jacques and Dr. Lebwohl discuss how they navigate the "shared decision-making" conversation by presenting patients with the full spectrum of modern options, including ultraviolet light, oral pills, and biologics. Dr. Lebwohl notes that specific patient needs—such as the requirement for rapid clearance before a wedding or a job interview—often push the choice toward faster-acting biologics. Conversely, comorbidities play a decisive role; for instance, IL-17 blockers are preferred for patients with multiple sclerosis, while they are avoided in those with Crohn's disease. The experts also touch on the "moderate" patient population, noting that while some oral therapies have broader labels for less severe disease, recent head-to-head trials show that many patients find the convenience of an injection every three months to be superior to a daily pill. The discussion concludes by reaffirming that because every patient defines convenience and success differently, a personalized, conversational approach is the only way to optimize long-term adherence and outcomes.

The next episode in this series, ‘Emerging Updates in Psoriasis from 2026 AAD Annual Meeting,’ features the panelists discussing late-breaking data regarding next-generation oral therapies and the dramatic synergy between weight-loss medications and psoriasis treatments. Dr. Bhutani-Jacques and Dr. Lebwohl explore how these combined approaches significantly improve skin clearance and systemic health.

Explore how cutting inflammation in psoriasis may lower heart risks, and why new oral TYK2 inhibitors could broaden treatment beyond injections.

Starting Treatment: Educating Patients and Initiating PERT for EPI

Once a diagnosis—or high clinical suspicion—is established, the panel turns to what comes next: patient education, treatment initiation, and supportive care coordination. Jennifer Geremia leads with the importance of educating patients that EPI is a long-term condition requiring long-term therapy. Without this foundational understanding, patients often stop therapy or take it inconsistently—since timing relative to meals is critical, any deviation compromises efficacy.

Sarah Enslin emphasizes setting realistic expectations from the start: patients should know what to anticipate in terms of timeframe for improvement and understand that dose adjustments are routine and do not indicate disease progression. She introduces the weight-based dosing framework and advises that providers build in a check-in at one to two weeks to assess and adjust. Capsules must always be taken with meals—not opened and sprinkled directly—though mixing with applesauce is acceptable as long as consumption is immediate.

The panel discusses ancillary support services with enthusiasm. Smoking and alcohol cessation are flagged as mandatory conversations, now embedded in their electronic health record workflows. Nutrition consults are described as transformative—a dietitian's ability to help patients maintain a pancreas-friendly diet within the constraints of their cultural preferences, financial resources, and lifestyle is something no provider can fully replicate. The shortage of dietitians in gastroenterology practice is explicitly called out as an unmet need.

Checking fat-soluble vitamin levels (A, D, E, K) at diagnosis and supplementing as needed is highlighted as an early, high-priority step. The panel also advocates for psychological support—particularly cognitive behavioral therapy—for patients who develop food fear or social anxiety. Palliative care is increasingly being invoked earlier in the care pathway, particularly for severely debilitated patients with chronic pancreatitis, to address pain and nutritional rehabilitation and break the cycle of repeated emergency department visits.

Optimizing PERT: Dosing, Adjustments, and Managing Non-Responders in EPI

," the panel provides practical guidance on fine-tuning PERT therapy—covering weight-based dosing, the role of PPIs, uric acid considerations, and strategies for patients who fail to respond to initial treatment.

Learn what happens after suspected EPI: patient education, enzyme therapy tips, nutrition and vitamin checks, plus smoking and alcohol support.

Video Series

Learn how chelators and zinc manage copper in Wilson disease, why trientine is favored, and when maintenance therapy becomes lifelong.

Therapeutic Strategies in Wilson Disease

Newborn screening spots Wilson’s disease sooner, helping stop copper buildup and irreversible neurologic damage—improving outcomes and daily life.

Impact of Early Diagnosis on Disease Progression and Quality of Life in Wilson Disease

Derm experts compare TYK2 pills with biologics for psoriasis—safety, speed, infections, and when combination therapy helps stubborn skin and joints.

Potential Therapeutic Opportunities of TYK2 Therapy Beyond Psoriasis and Identifying the Ideal Patient 

Clinicians weigh PEI questionnaires, symptom scores, and AGA updates to track exocrine pancreatic insufficiency and tailor patient-centered care.

Putting PROs to Work: The PEIQ and Symptom Scores in EPI Management

Podcasts

In this April episode, the discussion highlights how intentional choices and practice ownership can help physicians align professional with personal success.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

The Medical Sisterhood: Exposure is Power-Women in Medicine Creating Opportunity, With Elizabeth Kiracofe MD

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

This Q&A interview with Nambudiri covers the AAD Clinical Image Collection, launched in January 2025 to address diversity in dermatology education.



Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Q&A: How Dermatologists Can Utilize the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH

Tatyana Kushner, MD, is an associate professor of medicine in the division of gastroenterology and hepatology at Weill Cornell Medicine.

Brelovitug achieved the FDA-specified primary endpoint for HDV RNA reduction and normalization of ALT in a phase 2b trial.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

AZURE-1: Brelovitug Meets Key Endpoints in Hepatitis D, With Tatyana Kushner, MD

Julie Silverstein, MD, is the medical director of the pituitary center and of the clinical trials unit and professor of medicine and neurological surgery at WashU Medicine.

Silverstein addresses a secondary analysis of the GRACE trial, highlighting relacorilant’s efficacy in reducing cortisol in patients taking GLP-1 RAs.

Relacorilant Reduces HbA1c in Cushing’s Despite GLP-1 Treatment, With Julie Silverstein, MD

Low-dose radiation therapy is gaining attention in the US for osteoarthritis and inflammatory pain, with clinicians citing anti-inflammatory effects.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

Strategic Alliance Partnership

Low-Dose Radiation Therapy Gains Traction in US, With Hirsch Sudhir Matani, MD

Baba Inusa, MBBS, is a Consultant Paediatrician in the School of Life Course & Population Sciences at King's College London.

Inusa discusses how clinicians can close gaps in sickle cell disease care and global disparities. 

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Latest News

Real-World Data Reinforces Paltusotine’s IGF-1 Reductions in Acromegaly, With Leena Shahla, MD

25 mcg JJA Venom Immunotherapy Matches 50 mcg Efficacy, With Adriana Le Thanh-Thao, MBBS

Oral Deucrictibant Reduces HAE Attack Severity in 4 Hours During Phase 2 RAPIDe-1

Patient Preferences and Shared Decision-Making in Psoriasis Care

Starting Treatment: Educating Patients and Initiating PERT for EPI